Live
- PM Modi receives ceremonial welcome in Abuja, begins bilateral talks with Nigerian President Tinubu
- Goods traffic doubles on the new railway freight corridors
- BGT 2024-25: I’d like to see him make one more Test ton in Australia, says Johnso
- Harassment due to ED raids forced Kailash Gehlot to quit, hints Kejriwal
- Kailash Gehlot exit: BJP goes on the offensive against 'corrupt' AAP govt
- PM Modi pays homage to ‘the great’ Balasaheb Thackeray on his death anniversary
- One who cares for Delhi will not stay with gang of robbers: Sachdeva on Gahlot's resignation
- From Self-Doubt to Self-Love: Vange Cain’s Inspirational Path
- Rahul Gandhi remembers Balasaheb Thackeray on his death anniversary
- Tomato prices drop 22.5 pc as flow of fresh crop picks up pace
Dr Reddy’s gets establishment inspection report from FDA for Srikakulam unit
Dr Reddy’s Laboratories (DRL) has received an establishment inspection report (EIR) from the US FDA for its Srikakulam formulations facility in Andhra Pradesh.
Hyderabad: Dr Reddy’s Laboratories (DRL) has received an establishment inspection report (EIR) from the US FDA for its Srikakulam formulations facility in Andhra Pradesh.
“With regard to the audit of the company’s formulation Srikakulam Plant (SEZ) Unit I, Andhra Pradesh, the company has received an EIR from the US health regulator, for the above-referred facility,” Dr Reddy’s informed BSE in a communique.
The US FDA issues an EIR to the establishment that is the subject of an FDA or FDA-contracted inspection when the agency decides to close the inspection. In last June, the US health regulator had issued one observation after the inspection of the unit. Dr Reddy’s, however, did not disclose details about the observation.
Shares of Dr Reddy’s Laboratories closed higher by Rs60.35 or 2.62 percent at Rs2,367.85 on BSE. The stock on NSE gained three per cent and closed at Rs 2,375.40.
